Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer With Enzalutamide and the Poly (ADP- Ribose) Polymerase (PARP) Inhibitor Niraparib: Hoosier Cancer Research Network GU14-202
Sponsor: Hoosier Cancer Research Network
Terminated
Suspended by funder
Other terminated trials from Hoosier Cancer Research Network
Other Metastatic Prostate Cancer trials with similar outcome
Listed as NCT02500901, this PHASE1 trial focuses on Metastatic Prostate Cancer and remains terminated or withdrawn. Sponsored by Hoosier Cancer Research Network, it has been updated 10 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Nov 2018 — Nov 2019 [monthly]
Terminated PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Terminated PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoosier Cancer Research Network
- Paul Mathew, MD
- Tesaro, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .